Literature DB >> 31976810

Suppression of TGF-β and IL-10 receptors on self-differentiated dendritic cells by short-hairpin RNAs enhanced activation of effector T-cells against cholangiocarcinoma cells.

Chutamas Thepmalee1,2,3, Aussara Panya1,4,5, Jatuporn Sujjitjoon1, Nunghathai Sawasdee1, Naravat Poungvarin6, Mutita Junking1, Pa-Thai Yenchitsomanus1.   

Abstract

Cholangiocarcinoma (CCA) is an aggressive tumor that is associated with high rates of recurrence and mortality. This is due, in part, to the fact that CCA cells and their microenvironment secrete immunosuppressive cytokines, transforming growth factor-β (TGF-β) and interleukin-10 (IL-10), that inhibit dendritic cell (DC) functions, which, in turn, results in the decreased anti-tumor activity of T-cells. We hypothesized that the TGF-β receptor and IL-10 blockade on dendritic cells would improve DC function, thereby allowing improved activation of T cells against CCA cells. To test our hypothesis, we generated self-differentiated DCs (SD-DCs) via transduction of human peripheral blood monocytes with lentivirus expressing IL-4 and GM-CSF. SD-DCs were transduced with a second lentivirus containing short-hairpin RNAs (shRNAs) to knock-down TGF-βRII and IL-10RA mRNAs. Immunoblot confirmed the reduced expression levels of TGF-β and IL-10 receptors in both SD-DCs that were transduced with a single and/or combination of lentiviruses containing shRNAs. SD-DCs were thereafter pulsed with tumor antigens extracted from CCA cell lines in an effort to activate DC function. MHC class II (HLA-DR) and co-stimulatory molecules (CD40 and CD86) on SD-DCs were upregulated to levels comparable to those on DCs generated by the conventional method. Suppression of TGF-β and IL-10 receptors on SD-DCs influenced the effector T-cells to produce IFN-γ, which enhanced their ability to kill CCA cells. The preparation of adoptive effector T-cells holds the potential of becoming a novel therapy for cellular immunotherapy in CCA.

Entities:  

Keywords:  IL-10 receptor; Self-differentiated dendritic cells; TGF-β receptor; cellular immunotherapy; cholangiocarcinoma; immunosuppressive cytokines

Year:  2020        PMID: 31976810      PMCID: PMC7644170          DOI: 10.1080/21645515.2019.1701913

Source DB:  PubMed          Journal:  Hum Vaccin Immunother        ISSN: 2164-5515            Impact factor:   3.452


  19 in total

Review 1.  IL-4: an important cytokine in determining the fate of T cells.

Authors:  J L Silva-Filho; C Caruso-Neves; A A S Pinheiro
Journal:  Biophys Rev       Date:  2014-01-09

2.  The siRNA cocktail targeting interleukin 10 receptor and transforming growth factor-β receptor on dendritic cells potentiates tumour antigen-specific CD8(+) T cell immunity.

Authors:  Y-H Ahn; S-O Hong; J H Kim; K H Noh; K-H Song; Y-H Lee; J-H Jeon; D-W Kim; J H Seo; T W Kim
Journal:  Clin Exp Immunol       Date:  2015-05-17       Impact factor: 4.330

Review 3.  Current insights on cholangiocarcinoma research: a brief review.

Authors:  Vivek Bhakta Mathema; Kesara Na-Bangchang
Journal:  Asian Pac J Cancer Prev       Date:  2015

4.  Inhibition of IL-10 and TGF-β receptors on dendritic cells enhances activation of effector T-cells to kill cholangiocarcinoma cells.

Authors:  Chutamas Thepmalee; Aussara Panya; Mutita Junking; Thaweesak Chieochansin; Pa-Thai Yenchitsomanus
Journal:  Hum Vaccin Immunother       Date:  2018-02-21       Impact factor: 3.452

5.  Significance of alternatively activated macrophages in patients with intrahepatic cholangiocarcinoma.

Authors:  Horlad Hasita; Yoshihiro Komohara; Hirohisa Okabe; Toshiro Masuda; Koji Ohnishi; Xiao F Lei; Toru Beppu; Hideo Baba; Motohiro Takeya
Journal:  Cancer Sci       Date:  2010-05-12       Impact factor: 6.716

6.  Enhanced cytotoxic activity of effector T-cells against cholangiocarcinoma by dendritic cells pulsed with pooled mRNA.

Authors:  Mutita Junking; Janya Grainok; Chutamas Thepmalee; Sopit Wongkham; Pa-Thai Yenchitsomanus
Journal:  Tumour Biol       Date:  2017-10

7.  Cytotoxic activity of effector T cells against cholangiocarcinoma is enhanced by self-differentiated monocyte-derived dendritic cells.

Authors:  Aussara Panya; Chutamas Thepmalee; Nunghathai Sawasdee; Jatuporn Sujjitjoon; Nattaporn Phanthaphol; Mutita Junking; Sopit Wongkham; Pa-Thai Yenchitsomanus
Journal:  Cancer Immunol Immunother       Date:  2018-07-28       Impact factor: 6.968

8.  DC immunotherapy is highly effective for the inhibition of tumor metastasis or recurrence, although it is not efficient for the eradication of established solid tumors.

Authors:  Dae-Seog Lim; Jeong-Hwan Kim; Dong-Seong Lee; Cheol-Hee Yoon; Yong-Soo Bae
Journal:  Cancer Immunol Immunother       Date:  2007-04-19       Impact factor: 6.968

Review 9.  The challenge of cholangiocarcinoma: dissecting the molecular mechanisms of an insidious cancer.

Authors:  Abigail Zabron; Robert J Edwards; Shahid A Khan
Journal:  Dis Model Mech       Date:  2013-03       Impact factor: 5.758

10.  Vaccination of recurrent glioma patients with tumour lysate-pulsed dendritic cells elicits immune responses: results of a clinical phase I/II trial.

Authors:  R Yamanaka; T Abe; N Yajima; N Tsuchiya; J Homma; T Kobayashi; M Narita; M Takahashi; R Tanaka
Journal:  Br J Cancer       Date:  2003-10-06       Impact factor: 7.640

View more
  5 in total

Review 1.  Intrahepatic cholangiocarcinoma: Morpho-molecular pathology, tumor reactive microenvironment, and malignant progression.

Authors:  Alphonse E Sirica; Mario Strazzabosco; Massimiliano Cadamuro
Journal:  Adv Cancer Res       Date:  2020-12-09       Impact factor: 6.242

Review 2.  The Emerging Role of Immunotherapy in Intrahepatic Cholangiocarcinoma.

Authors:  Oraianthi Fiste; Ioannis Ntanasis-Stathopoulos; Maria Gavriatopoulou; Michalis Liontos; Konstantinos Koutsoukos; Meletios Athanasios Dimopoulos; Flora Zagouri
Journal:  Vaccines (Basel)       Date:  2021-04-22

Review 3.  The Functional Roles of Immune Cells in Primary Liver Cancer.

Authors:  Linh Pham; Konstantina Kyritsi; Tianhao Zhou; Ludovica Ceci; Leonardo Baiocchi; Lindsey Kennedy; Sanjukta Chakraborty; Shannon Glaser; Heather Francis; Gianfranco Alpini; Keisaku Sato
Journal:  Am J Pathol       Date:  2022-03-23       Impact factor: 5.770

Review 4.  Targeting protein kinase CK2 in the treatment of cholangiocarcinoma.

Authors:  Padma-Sheela Jayaraman; Kevin Gaston
Journal:  Explor Target Antitumor Ther       Date:  2021-10-31

Review 5.  Tumor Microenvironment and its Implications for Antitumor Immunity in Cholangiocarcinoma: Future Perspectives for Novel Therapies.

Authors:  Hengsong Cao; Tian Huang; Mingrui Dai; Xiangyi Kong; Hanyuan Liu; Zhiying Zheng; Guoqiang Sun; Guangshun Sun; Dawei Rong; Zehua Jin; Weiwei Tang; Yongxiang Xia
Journal:  Int J Biol Sci       Date:  2022-08-21       Impact factor: 10.750

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.